Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
Toronto, Ontario--(Newsfile Corp. - October 16, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-10-16 8:55 AM EDT | Rhelion Life Sciences Corp.
LIS Technologies Granted U.S. Nuclear Regulatory Commission Approval of Standard Practice Procedures Plan for Its State-of-the-Art Demonstration Facility in Oak Ridge, TN
Oak Ridge, Tennessee--(Newsfile Corp. - October 15, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a company developing the only U.S.-origin and patented advanced laser uranium enrichment technology, today announced that the United States Nuclear Regulatory Commission (NRC) has approved LIST's Standard Practice Procedures Plan (SPPP) for its Test Demonstration Facility in Oak Ridge, Tennessee. This approval follows LIST's initial SPPP submission on February 11, 2026. Th
Technology, Mining and Metals, Energy, Health
2026-10-15 8:29 AM EDT | LIS Technologies Inc.
Extendicare Announces October 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - October 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of October 2026, which is payable on November 16, 2026 to shareholders of record at the close of business on October 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-15 8:00 AM EDT | Extendicare Inc.
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations. In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead ca
2026-10-15 8:00 AM EDT | BetterLife Pharma Inc.
Promino Secures Social Commerce Distribution Agreement for US$5 Million Minimum Product Purchases
Burlington, Ontario--(Newsfile Corp. - October 15, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a muscle health and performance nutrition company, announces that Promino and its subsidiaries have entered into a Distribution and Marketing Services Agreement (the "Agreement") dated October 15, 2026 with Social Commerce Brands Inc. ("SCB"). SCB will focus on the distribution and marketing of Rejuvenate Muscle Health™ through
Food / Beverages, Sports, Health
2026-10-15 7:00 AM EDT | Promino Nutritional Sciences, Inc.
TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-15 3:05 AM EDT | TempraMed Technologies Ltd.
Doseology Announces Resignation of Director
Kelowna, British Columbia--(Newsfile Corp. - October 14, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announces that Larry Latowsky has resigned as a director of the Company, effective immediately. About Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70)
2026-10-14 6:00 PM EDT | Doseology Sciences Inc.
Unbuzzd Wellness Announces Loan Amendment, Warrant Cancellation, and Acquisition of Licensed Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, announces that it entered into a second loan amending agreement (the "Loan Amendment") and a warrant cancellation and release agreement (the "Warrant Cancellation Agreement") with Quantum BioPharma Ltd. ("Quantum") on October 13, 2026. LOAN AMENDMENT The Loan Amendment extends the maturity date of the Company's secured loan
2026-10-14 4:56 PM EDT | Unbuzzd Wellness Inc.
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
Toronto, Ontario--(Newsfile Corp. - October 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-10-14 8:34 AM EDT | Rhelion Life Sciences Corp.
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the formation of a Scientific Advisory Board ("SAB") to guide the clinical development of BETR-001. Professor Peter Goadsby, MD, PhD, FRS, has been appointed Co-Chair. The SAB will advise the Company's manage
2026-10-14 8:00 AM EDT | BetterLife Pharma Inc.
Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position
Winter Park, Florida--(Newsfile Corp. - October 13, 2026) - Adia Med, Inc. (OTCQB: ADIA) (the "Company") today announced the full repayment and discharge of its unsecured revolving line of credit with Larry Powalisz, the Company's Chief Executive Officer.
Healthcare and Hospitals, Health
2026-10-13 9:00 AM EDT | Adia Med Inc.
Altrova Health Announces Closing of Financing
Toronto, Ontario--(Newsfile Corp. - October 13, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce that, further to its news releases dated September 8, 2026, it has closed its non-brokered private placement (the "Offering") for total gross proceeds of C$669,840. Gross proceeds were raised through the issuance of 13,396,800 units (the "Units") at a price of $0.05 per Unit. Each Unit con
2026-10-13 7:07 AM EDT | Altrova Health Inc.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstra
Biotechnology, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | BioHarvest Sciences Inc.
Tersis Technologies and The Salem Group Sign MOU to Evaluate a Venezuela Joint Venture for Waste-to-Value Distributed Power
Miami, Florida--(Newsfile Corp. - October 12, 2026) - Tersis Technologies, Inc. (OTCID: TERS), a clean technology company advancing waste-to-value and circular infrastructure solutions, today announced that it has signed a Memorandum of Understanding with The Salem Group USA, LLC ("Salem"), a Miami-based
Agriculture, Energy, Alternative Energy, Health
2026-10-12 10:12 AM EDT | Tersis Technologies Inc.
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today issued a statement regarding a Notice of Civil Claim ("Claim") filed against the Company by Steven Sangha, an independent director of BetterLife, in the Supreme Court of British Columbia on October 8, 2026. As disclosed in the Company's unaudited interim financial statements and management's discussion and analysis for Jul
2026-10-09 3:00 PM EDT | BetterLife Pharma Inc.
Edison Issues Report on Molecule Group (MOL)
London, United Kingdom--(Newsfile Corp. - October 9, 2026) - Edison issues report on Molecule Group (AIM: MOL). Molecule Group (formerly Vulcan Two) was founded in 2025 to consolidate the regulated e-pharmacy market in the UK, with a focus on the growing private healthcare market, and led by founders who successfully consolidated the online contact lens market. It has since acquired three businesses with B2B and B2C exposure to the private e-pharmacy market. The plan to create a single
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-10-09 7:26 AM EDT | Edison Group
Psyched Wellness Announces Secured Term Loan
Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCID: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregate p
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-10-08 5:15 PM EDT | Psyched Wellness Ltd.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-10-08 10:01 AM EDT | Breathe BioMedical Inc.
LIS Technologies Inc. Announces Major Milestone with the Receipt of an Initial Shipment of Uranium Hexafluoride (UF6) to be Leveraged at its State-of-the-Art Demonstration Test Loop Facility
Oak Ridge, Tennessee--(Newsfile Corp. - October 8, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced a major developmental milestone with the acceptance of its initial shipment of UF₆ for the demonstration and optimization of its CRISLA-4G process at its Test Demonstration Facility in Oak Ridge, Tennessee. Building on LIST
Technology, Mining and Metals, Energy, Health
2026-10-08 8:29 AM EDT | LIS Technologies Inc.